Bacterial co-abundance networks decreases in complexity with lower host genetic variation. by Michael Ørsted (5926028)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Decrease of C/EBPβ protein expression attenuates DEX-induced repression of CBG mRNA and protein levels and reduces GR recruitment to the mouse <i>Cbg</i> promoter. by Nicolette Verhoog (647814)

“…Occupancy of GR protein on the endogenous mouse <i>Cbg</i> promoter was detected using primers encompassing the regions defined as P5 to P1. …”

Image_1_ACEI/ARB Medication During ICU Stay Decrease All-Cause In-hospital Mortality in Critically Ill Patients With Hypertension: A Retrospective Cohort Study Based on Machine Lea... by Boshen Yang (11935403)

Table_1_ACEI/ARB Medication During ICU Stay Decrease All-Cause In-hospital Mortality in Critically Ill Patients With Hypertension: A Retrospective Cohort Study Based on Machine Lea... by Boshen Yang (11935403)

Identification of metabolites with cell type-specific-dynamics reveals the amino acid class as highly conserved in hiPSC and hNSC and that most of the cell type-specific amino acid... by João Vasconcelos e Sá (8721594)

The pGT insert in BG00076 decreases <i>Skip</i> expression level. by Narelle E. Tunstall (170446)

“…There is an approximately five fold decrease of <i>Skip</i> transcription in line BG00076. *** p<0.001 t-test.…”

Mice carrying 100P mutations show layer-specific decreases in proportions of PV+ cells. by Malgorzata Borkowska (3166719)

“…<p>(<b>A-D</b>) Decreases occurred in layer IV in fSSp, SSp, vAud and Vis, in layer V in SSp, vAud and Vis and in layer II/III in SSp. …”

S5 Raw image - by Zhi Xuan Low (19270163)

“…This study also revealed a notable sequential reduction in serum levels of tumour markers, including carcinoembryonic antigen (CEA) and mouse Cytochrome P450 1A2 (CYP1A2), correlating with a significant decrease in tumour bulk volume upon treatment commencement. …”

<i>HD</i> CAG and 3-NP Shared Decreased Expression of Glycolytic Genes by Jong-Min Lee (105338)

“…<p>The energy metabolism pathway gene expression changes common to mutant striatal cells (<i>HD</i> CAG, red) and 3-NP treated wild-type striatal cells (3-NP, green) are shown, with fold-change, compared to wild-type striatal cells, highlighting decreased cytosolic glycolytic processes (numbered 1–11). …”

Does a correlation exist between delayed vaccination and a decreased vaccine confidence? by Virginia Reverte (9046494)

“…Vaccine Confidence Index (VCI) is an indicator to estimate confidence in vaccines, composed of simple dimensions about it and evaluated using a 5-point Likert scale. Objectives of this study, conducted in the Region of Murcia, Spain, were to determine which sociodemographic factors were associated with delayed administration in measles, mumps and rubella (MMR) vaccine, both first and second doses, and to evaluate if there were differences in parental vaccine confidence of children who were delayed on MMR vaccine schedule compare to vaccinated on time. …”

PSMα3N22Y has decreased chemotactic activity toward human neutrophils. by Gordon Y. C. Cheung (337723)

Effects of Cu (5 µM) pretreatment on Hcy-induced decrease in cell viability and LDH release. by Daoyin Dong (424519)

The percentages of genes with largely changed expression after AdNKX2-1 infection. by Yuko Ito (1976692)